期刊文献+

巨块型宫颈癌术前新辅助化疗的疗效观察(附60例分析) 被引量:2

Efficiency of neoadjuvant chemotherapy in preoperative management of bulky cervical carcinoma
暂未订购
导出
摘要 目的探讨巨块型宫颈癌术前新辅助化疗的治疗效果。方法对我院收治的6 0例Ⅰb~Ⅱa期巨块型宫颈癌进行回顾性分析,根据术前是否行新辅助化疗(Neoadjuvant Chemotherapy,NACT)分为两组,即NACT组和单纯手术对照组,各3 0例。NACT组术前行1~2个疗程以铂类为基础的联合化疗,化疗结束后2周行宫颈癌根治术。观察化疗后局部肿瘤退缩情况及化疗不良反应,并比较两组手术效果。结果 (1)NACT组化疗后肿瘤直径较化疗前明显缩小(P〈0.0 5),总有效率为7 3.3%,近期不良反应轻;(2)NACT组的手术时间、术中出血量明显低于对照组(P〈0.0 5),两组术后胃肠道功能恢复时间及膀胱功能恢复时间差异无计学意义(P〉0.0 5);(3)NACT组术后高危病理因素发生率低于对照组,但差异无统计学意义(P〉0.0 5)。结论巨块型宫颈癌术前新辅助化疗可明显缩小原发灶,减少手术时间及出血量,且不影响患者术后恢复,临床上值得推广应用。 Objective To investigate the efficiency of neoadjuvant chemotherapy(NACT)in preoperative management of bulky cervicai carcinoma.Methods Sixty cases of stage Ⅰb~Ⅱa cervical carcinoma patients were divided into two groups according to pre-operative chemotherapy:thirty cases in the NACT group who accepted 1~2 courses of platinum-based chemotherapy before surgery;and another thirty cases in the control group underwent radical surgery directly.The tumor volume was evaluated by gynecological examination before chemotherapy and two weeks after chemotherapy,and the complication of chemotherapy was observed at the same time.The surgical efficiency of two groups was compared at last.Results Tumor volume was significant reduced after chemotherapy,the overall effective rate was 73.3%,and the incidence of complication was quite low.The operation time and blood loss of NACT group were significant lower than those of control group(P0.05),but there was no significant difference between the two groups about gastrointestinal function restoring time and bladder function restoring time(P0.05).The rate of lymphatic metastasis,vessel invasion,deep stromal invasion and parametrial invasion in NACT group were lower than which in control group,while neither with statistical significance(P0.05).Conclusion Preoperative neoadjuvant chemotherapy can reduce the primary tumor volume and benefit to the following radical operation,which is worth popularizing in clinical treatment.
出处 《福建医药杂志》 CAS 2011年第3期3-5,共3页 Fujian Medical Journal
关键词 宫颈肿瘤 巨块型 辅助化学疗法 cervical neoplasm bulky chemotherapy
  • 相关文献

参考文献12

二级参考文献39

  • 1宋水勤,张国楠.宫颈癌新辅助化疗现状[J].实用医院临床杂志,2005,2(2):22-25. 被引量:53
  • 2王平,彭芝兰,张家文,刘辉,张崇淑,曹泽毅.子宫颈癌新辅助化疗中不同化疗途径的疗效比较[J].中华妇产科杂志,2005,40(4):227-230. 被引量:109
  • 3邸石,江大琼.25例宫颈癌新辅助化疗临床分析[J].华中医学杂志,2005,29(6):433-434. 被引量:14
  • 4尹凤玲,韩素萍.新辅助化疗——宫颈癌治疗中的新趋势[J].国外医学(计划生育.生殖健康分册),2006,25(4):212-214. 被引量:11
  • 5Goldberg JM, Piver MS, Hempling RE, et al. Paclitaxel and cisplatin combination chemo - therapy in recurrent epithelial ovarian cancer[ J]. Gyncol Oncol, 1996,63:312 - 317.
  • 6Mcguire WP,Hoskins WJ, Brady MF,et al. Cyclophosphamide and cisphin compared with paclitaxel and cisplatin in patients with stage Ⅲ and Ⅳ ovarian cancer[ J]. N Engl J Med, 1996,334:1 - 6.
  • 7Bhallak, Huang Y, Tang C, et al, Taxol induces intemaclovsomd DNA fragmentation associated with programmed cell cleath in human myeloid leukemia cell [ J ]. Leukemia, 1993,7 : 563 - 575.
  • 8Patricia JE,Ivenback C.Cancer of the female lower genitahract[M].London:BC Decker lnc,Hamilton,2001:272-273.
  • 9Nagata Y,Okajiama K,Kokubo M,et al.Clinical results of transcathe ter arterial infusion for uterine cervical cancer[J].Am J Ciin Oncol Cancer Clin Trials,1999,22(1):97-102.
  • 10Benedetti-Panici P,Greggi S,Colombo A,et al.Neoadjuvant chemotherapy and radical surgery remus exclusive radiotherapy in locally advanced squamous cell cervical cancer:results from the Italian multi center randomized study[J].J Clin Oncol,2002,20(1):179-188.

共引文献66

同被引文献18

  • 1张凡,常永霞,张九鸿,成日青,赵秀芳.早期宫颈癌耐药基因与临床预后关系回顾性研究[J].河北北方学院学报(医学版),2006,23(1):1-7. 被引量:2
  • 2高国兰,万红英,邹学森,陈文学,陈岳青,黄秀珍.子宫颈癌组织三磷酸腺苷肿瘤体外药物敏感试验及其与耐药蛋白表达的关系[J].中华妇产科杂志,2007,42(3):201-205. 被引量:9
  • 3Gong L,Lou JY,Wang P. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage I b2-IIb cervical cancer[J].International Journal of Gynecology and Obstetrics,2012,(01):23-26.
  • 4Takara K,Sakaeda T,Okumura K. An update on overcoming MDR1 mediated multidrug resistance in cancer chemotherapy[J].Curr Pham Des,2006,(03):273.
  • 5Sharom FJ. Shedding light on drug transport:structure and function of the P-glycoprotein multidrug transporter[J].Biochemistry and Cell Biology-Biochimie et Biologie Cellulaire,2006,(06):979-992.
  • 6Patel S,Keller BA,Fisher LM. Mutations at arg 486 and glu 571 in human topoisomerase Ⅱalpha confer resistance to amsacrine:relevance for antitumor drug resistance in human cells[J].Molecular Pharmacology,2000,(04):784.
  • 7Konishi I,Nanbu K,Mandai M. Tumor response to neoadjuvant chemotherapy correlate with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma[J].Gynecologic Oncology,1998,(03):365.
  • 8Branca M,Giorgi C,Ciotti M. Over-expression of topoisomerase Ⅱalpha is related to the grade of cervical intraepithelial neoplasia and high-risk human papilloma virus(HPV),but does not predict prognosis in cervical cancer or HPV clearance after cone treatment[J].International Journal of Gynecological Pathology,2006,(04):383.
  • 9曾四元,梁美蓉,于晓红,魏宝秀,吴云燕,李隆玉.P-gp、GST-π、Topo-Ⅱ在宫颈癌组织中的表达及意义[J].实用癌症杂志,2008,23(3):256-259. 被引量:10
  • 10杨晓文,崔明,莫平.术前化疗对乳腺癌组织中谷胱甘肽-s-转移酶-π、P-糖蛋白和拓扑异构-Ⅱ表达的影响[J].中华乳腺病杂志(电子版),2009,3(1):35-38. 被引量:8

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部